The DOI matches its Crossref record; 130 of the 130 references it cites were found in a registry or an index.
Recent developments in adenosine receptor ligands and their potential as novel drugs
Open accessAbstract
Medicinal chemical approaches have been applied to all four of the adenosine receptor (AR) subtypes (A1, A2A, A2B, and A3) to create selective agonists and antagonists for each. The most recent class of selective AR ligands to be reported is the class of A2BAR agonists. The availability of these selective ligands has facilitated research on therapeutic applications of modulating the ARs and in some cases has provided clinical candidates. Prodrug approaches have been developed which improve the bioavailability of the drugs, reduce side-effects, and/or may lead to site-selective effects. The A2A agonist regadenoson (Lexiscan®), a diagnostic drug for myocardial perfusion imaging, is the first selective AR agonist to be approved. Other selective agonists and antagonists are or were undergoing clinical trials for a broad range of indications, including capadenoson and tecadenoson (A1 agonists) for atrial fibrillation, or paroxysmal supraventricular tachycardia, respectively, apadenoson and binodenoson (A2A agonists) for myocardial perfusion imaging, preladenant (A2A antagonist) for the treatment of Parkinson’s disease, and CF101 and CF102 (A3 agonists) for inflammatory diseases and cancer, respectively. This article is part of a Special Issue entitled: “Adenosine Receptors”.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors
Fredholm, B. B., IJzerman, A. P., Jacobson, K. A., Klotz, K.-N., & Linden, J. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01511-4 · Cited by 2,585
Self-citationThe 2.6 Angstrom Crystal Structure of a Human A 2A Adenosine Receptor Bound to an Antagonist
Jaakola, V.-P., Griffith, M. T., Hanson, M. A., Cherezov, V., Chien, E. Y. T., Lane, J. R., IJzerman, A. P., & Stevens, R. C. (2008) · Science · doi:10.1126/science.1164772 · Cited by 1,781
Adenosine Receptors as Therapeutic Targets
Jacobson, K. A., & Gao, Z.-G. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1983 · Cited by 1,431 · cited 1×
“A1 receptor antagonists—Various A1AR antagonists, xanthines and nonxanthines, have been or are currently being explored for clinical applications [109] for heart failure, and for improving renal function and treatment of acute renal failure.”
BackgroundSelf-citationFredholm, B. B., IJzerman, A. P., Jacobson, K. A., Linden, J., & Müller, C. E. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003285 · Cited by 1,301
Self-citationDopamine D 1 and adenosine A 1 receptors form functionally interacting heteromeric complexes
Ginés, S., Hillion, J., Torvinen, M., Le Crom, S., Casadó, V., Canela, E. I., Rondin, S., Lew, J. Y., Watson, S., Zoli, M., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.150241097 · Cited by 445
Cardioprotection by Ecto-5′-Nucleotidase (CD73) and A 2B Adenosine Receptors
Eckle, T., Krahn, T., Grenz, A., Köhler, D., Mittelbronn, M., Ledent, C., Jacobson, M. A., Osswald, H., Thompson, L. F., Unertl, K., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.669697 · Cited by 435
Adenosine A2A-Dopamine D2 Receptor-Receptor Heteromerization
Canals, M., Marcellino, D., Fanelli, F., Ciruela, F., de Benedetti, P., Goldberg, S. R., Neve, K., Fuxe, K., Agnati, L. F., Woods, A. S., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306451200 · Cited by 432
Molecular cloning and characterization of the human A3 adenosine receptor.
Salvatore, C. A., Jacobson, M. A., Taylor, H. E., Linden, J., & Johnson, R. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.21.10365 · Cited by 424
Building a new conceptual framework for receptor heteromers
Ferré, S., Baler, R., Bouvier, M., Caron, M. G., Devi, L. A., Durroux, T., Fuxe, K., George, S. R., Javitch, J. A., Lohse, M. J., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio0309-131 · Cited by 394
LeWitt, P. A., Guttman, M., Tetrud, J. W., Tuite, P. J., Mori, A., Chaikin, P., Sussman, N. M., & 6002‐US‐005 Study Group (2008) · Annals of Neurology · doi:10.1002/ana.21315 · Cited by 356
Iskandrian, A. E., Bateman, T. M., Belardinelli, L., Blackburn, B., Cerqueira, M. D., Hendel, R. C., Lieu, H., Mahmarian, J. J., Olmsted, A., Underwood, S. R., et al. (2007) · Journal of Nuclear Cardiology · doi:10.1016/j.nuclcard.2007.06.114 · Cited by 350
Detection of heteromerization of more than two proteins by sequential BRET-FRET
Carriba, P., Navarro, G., Ciruela, F., Ferré, S., Casadó, V., Agnati, L., Cortés, A., Mallol, J., Fuxe, K., Canela, E. I., et al. (2008) · Nature Methods · doi:10.1038/nmeth.1229 · Cited by 283
Structure-Based Discovery of Novel Chemotypes for Adenosine A2AReceptor Antagonists
Katritch, V., Jaakola, V.-P., Lane, J. R., Lin, J., IJzerman, A. P., Yeager, M., Kufareva, I., Stevens, R. C., & Abagyan, R. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901647p · Cited by 245
Baraldi, P. G., Tabrizi, M. A., Gessi, S., & Borea, P. A. (2008) · Chemical Reviews · doi:10.1021/cr0682195 · Cited by 238
Porkka-Heiskanen, T., Alanko, L., Kalinchuk, A., & Stenberg, D. (2002) · Sleep Medicine Reviews · doi:10.1053/smrv.2001.0201 · Cited by 236
Structure-Based Discovery of A 2A Adenosine Receptor Ligands
Carlsson, J., Yoo, L., Gao, Z.-G., Irwin, J. J., Shoichet, B. K., & Jacobson, K. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100240h · Cited by 227
Self-citationRegadenoson: A New Myocardial Stress Agent
Al Jaroudi, W., & Iskandrian, A. E. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.089 · Cited by 221
Adenosine: trigger and mediator of cardioprotection
Cohen, M. V., & Downey, J. M. (2008) · Basic Research in Cardiology · doi:10.1007/s00395-007-0687-7 · Cited by 218
Auchampach, J. A., Jin, X., Wan, T. C., Caughey, G. H., & Linden, J. (1997) · Molecular Pharmacology · doi:10.1124/mol.52.5.846 · Cited by 201
Adenosine receptor activation in human fibroblasts: nucleoside agonists and antagonists
Bruns, R. F. (1980) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y80-110 · Cited by 196
Elmenhorst, D., Meyer, P. T., Winz, O. H., Matusch, A., Ermert, J., Coenen, H. H., Basheer, R., Haas, H. L., Zilles, K., & Bauer, A. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.5066-06.2007 · Cited by 189
Li, A.-H., Moro, S., Forsyth, N., Melman, N., Ji, X.-D., & Jacobson, K. A. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980550w · Cited by 181
Self-citationA binding site model and structure-activity relationships for the rat A3 adenosine receptor.
van Galen, P. J., van Bergen, A. H., Gallo-Rodriguez, C., Melman, N., Olah, M. E., IJzerman, A. P., Stiles, G. L., & Jacobson, K. A. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10559-2 · Cited by 178
Self-citationKim, Y.-C., Ji, X.-D., Melman, N., Linden, J., & Jacobson, K. A. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990421v · Cited by 176
Self-citationStructure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists
Jacobson, K. A., Gallo‐Rodriguez, C., Melman, N., Fischer, B., Maillard, M. C., van Bergen, A., van Galen, P. J. M., & Karton, Y. (1993) · Journal of Medicinal Chemistry · doi:10.1021/jm00062a005 · Cited by 153
Self-citationProgress in the pursuit of therapeutic adenosine receptor antagonists
Moro, S., Gao, Z., Jacobson, K. A., & Spalluto, G. (2005) · Medicinal Research Reviews · doi:10.1002/med.20048 · Cited by 153
Self-citationBeukers, M. W., Chang, L. C. W., Künzel, J. K. V. F. D., Mulder‐Krieger, T., Spanjersberg, R. F., Brussee, J., & IJzerman, A. P. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049947s · Cited by 152
Prodrug Approaches for Enhancing the Bioavailability of Drugs with Low Solubility
Müller, C. E. (2009) · Chemistry & Biodiversity · doi:10.1002/cbdv.200900114 · Cited by 146
Self-citationFunctional characterization of the A2b adenosine receptor in NIH 3T3 fibroblasts
Brackett, L. E., & Daly, J. W. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90480-4 · Cited by 142
Antinociceptive Effects of Novel A2B Adenosine Receptor Antagonists
Abo‐Salem, O. M., Hayallah, A. M., Bilkei‐Gorzó, A., Filipek, B., Zimmer, A., & Müller, C. E. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.056036 · Cited by 141
Self-citationAdenosine receptor agonists: from basic medicinal chemistry to clinical development
Luo, Y., Burbiel, J. C., Maaß, A., & Müller, C. E. (2003) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.8.2.537 · Cited by 139
Self-citationAdenosine A2Areceptor activation attenuates inflammation and injury in diabetic nephropathy
Awad, A. S., Huang, L., Ye, H., Duong, E. T. A., Bolton, W. K., Linden, J. M., & Okusa, M. D. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00310.2005 · Cited by 137
Gao, Z., Blaustein, J. B., Gross, A. S., Melman, N., & Jacobson, K. A. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00153-9 · Cited by 136
Self-citationXanthines as Adenosine Receptor Antagonists
Müller, C. E., & Jacobson, K. A. (2010) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-13443-2_6 · Cited by 133
Self-citationInternalization and desensitization of adenosine receptors
Klaasse, E., IJzerman, A. P., DeGrip, W. J., & Beukers, M. W. (2007) · Purinergic Signalling · doi:10.1007/s11302-007-9086-7 · Cited by 131
Adenosine receptors and their modulators
Müller, C. E., & Scior, T. (1993) · Pharmaceutica Acta Helvetiae · doi:10.1016/0031-6865(93)90012-u · Cited by 126
Self-citationIsoquinoline and Quinazoline Urea Analogues as Antagonists for the Human Adenosine A3Receptor
van Muijlwijk‐Koezen, J. E., Timmerman, H., der Goot, H. V., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000002u · Cited by 125
Kuno, A., Critz, S. D., Cui, L., Solodushko, V., Yang, X., Krahn, T., Albrecht, B., Philipp, S., Cohen, M. V., & Downey, J. M. (2007) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2007.05.016 · Cited by 123
Sauer, R., Maurinš, J. A., Reith, U., Fülle, F., Klotz, K., & Müller, C. E. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9911480 · Cited by 121
Self-citationMott, A. M., Nunes, E. J., Collins, L. E., Port, R. G., Sink, K. S., Hockemeyer, J., Müller, C. E., & Salamone, J. D. (2009) · Psychopharmacology · doi:10.1007/s00213-008-1441-z · Cited by 120
Self-citationChe, J., Chan, E. S. L., & Cronstein, B. N. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.038760 · Cited by 119
Desai, A., Victor-Vega, C., Gadangi, S., Montesinos, M. C., Chu, C. C., & Cronstein, B. N. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.007807 · Cited by 115
Kopecky, S. L., Aviles, R. J., Bell, M. R., Lobl, J. K., Tipping, D., Frommell, G., Ramsey, K. E., Holland, A. E., Midei, M. G., Jain, A. C., et al. (2003) · American Heart Journal · doi:10.1016/s0002-8703(03)00172-8 · Cited by 115
Adenosine receptor agonists for promotion of dermal wound healing
Valls, M. D., Cronstein, B. N., & Montesinos, M. C. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.11.002 · Cited by 111
The A2b adenosine receptor protects against vascular injury
Yang, D., Koupenova, M., McCrann, D. J., Kopeikina, K. J., Kagan, H. M., Schreiber, B. M., & Ravid, K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705563105 · Cited by 109
Lauro, C., Cipriani, R., Catalano, M., Trettel, F., Chece, G., Brusadin, V., Antonilli, L., van Rooijen, N., Eusebi, F., Fredholm, B. B., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.26 · Cited by 108
Medicinal Chemistry of Adenosine A3 Receptor Ligands
Müller, C. E. (2003) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026033392174 · Cited by 107
Self-citationAdenosine A2A antagonists with potent anti-cataleptic activity
Shimada, J., Koike, N., Nonaka, H., Shiozaki, S., Yanagawa, K., Kanda, T., Kobayashi, H., Ichimura, M., Nakamura, J., Kase, H., et al. (1997) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(97)00440-x · Cited by 105
Gillespie, R. J., Bamford, S. J., Botting, R., Comer, M., Denny, S., Gaur, S., Griffin, M., Jordan, A. M., Knight, A. R., Lerpiniere, J., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800961g · Cited by 104
A1 Adenosine Receptor Antagonists, Agonists, and Allosteric Enhancers
Kiesman, W. F., Elzein, E. O., & Zablocki, J. A. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-89615-9_2 · Cited by 102
Tchilibon, S., Joshi, B. V., Kim, S., Duong, H. T., Gao, Z., & Jacobson, K. A. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049580r · Cited by 101
Self-citationIndustry forum: Progress in pursuit of therapeutic A2Aantagonists
Kase, H. (2003) · Neurology · doi:10.1212/01.wnl.0000095219.22086.31 · Cited by 99
Todde, S., Moresco, R. M., Simonelli, P., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm0009843 · Cited by 98
Müller, C. E., Diekmann, M., Thorand, M., & Ozola, V. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00785-5 · Cited by 97
Self-citationMiddleton, R. J., Briddon, S. J., Cordeaux, Y., Yates, A. S., Dale, C. L., George, M. W., Baker, J. G., Hill, S. J., & Kellam, B. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061279i · Cited by 93
Jeong, L. S., Jin, D. Z., Kim, H. O., Shin, D. H., Moon, H. R., Gunaga, P., Chun, M. W., Kim, Y., Melman, N., Gao, Z., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm034098e · Cited by 92
Self-citationA1adenosine receptor agonists and their potential therapeutic applications
Elzein, E. O., & Zablocki, J. A. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802497284 · Cited by 92
Ivanov, A. A., Barak, D., & Jacobson, K. A. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801533x · Cited by 88
Self-citationUdelson, J. E., Heller, G. V., Wackers, F. J. T., Chai, A. U., Hinchman, D. A., Coleman, P. S., Dilsizian, V., DiCarli, M., Hachamovitch, R., Johnson, J. R., et al. (2004) · Circulation · doi:10.1161/01.cir.0000114523.03312.7d · Cited by 87
Müller, C. E., Thorand, M., Qurishi, R., Diekmann, M., Jacobson, K. A., Padgett, W. L., & Daly, J. W. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm011093d · Cited by 86
Self-citationBlocking Striatal Adenosine A2A Receptors: A New Strategy for Basal Ganglia Disorders
Müller, C. E., & Ferré, S. (2007) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488907779561772 · Cited by 86
Self-citationPurinergic receptors in gastrointestinal inflammation
Kolachala, V. L., Bajaj, R., Chalasani, M., & Sitaraman, S. V. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00454.2007 · Cited by 82
Worden, L. T., Shahriari, M., Farrar, A. M., Sink, K. S., Hockemeyer, J., Müller, C. E., & Salamone, J. D. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1396-0 · Cited by 81
Self-citationMaemoto, T., Tada, M., Mihara, T., Ueyama, N., Matsuoka, H., Harada, K., Yamaji, T., Shirakawa, K., Kuroda, S., Akahane, A., et al. (2004) · Journal of Pharmacological Sciences · doi:10.1254/jphs.fp0040359 · Cited by 79
Guzman, J., Yu, J. G., Suntres, Z. E., Bozarov, A., Cooke, H. J., Javed, N., Auer, H., Palatini, J., Hassanain, H. H., Cardounel, A. J., et al. (2006) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200608000-00014 · Cited by 77
Pretorius, J., Malan, S. F., Castagnoli, N., Bergh, J. J., & Petzer, J. P. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.07.088 · Cited by 77
Müller, C. E., Geis, U., Hipp, J., Schobert, U., Frobenius, W., Pawłowski, M., Suzuki, F., & Sandoval-Ramı́rez, J. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm970515+ · Cited by 76
Self-citationMadi, L., Cohen, S., Ochayin, A., Bar‐Yehuda, S., Barer, F., & Fishman, P. (2007) · PubMed · Cited by 76
Kim, S., Marshall, M. A., Melman, N., Kim, H. S., Müller, C. E., Linden, J. M., & Jacobson, K. A. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm0104318 · Cited by 74
Self-citationLigand-Based Homology Modeling as Attractive Tool to Inspect GPCR Structural Plasticity
Moro, S., Deflorian, F., Bacilieri, M., & Spalluto, G. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206777585265 · Cited by 73
Suppression of inflammatory and immune responses by the A2Aadenosine receptor: an introduction
Palmer, T. M., & Trevethick, M. A. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707524 · Cited by 72
Giffin, N., Kowacs, F., Libri, V., Williams, P. M., Goadsby, P. J., & Kaube, H. (2003) · Cephalalgia · doi:10.1046/j.1468-2982.2003.00511.x · Cited by 72
Arispe, N. J., Ma, J., Jacobson, K. A., & Pollard, H. B. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.10.5727 · Cited by 71
Self-citation11C-labeled KF18446: a potential central nervous system adenosine A2a receptor ligand.
Ishiwata, K., Noguchi, J., Wakabayashi, S., et al. (2000) · PubMed · Cited by 71
In vivo imaging of adenosine A2A receptors in rat and primate brain using [11C]SCH442416
Moresco, R. M., Todde, S., Belloli, S., Simonelli, P., Panzacchi, A., Rigamonti, M. M., Galli-Kienle, M., & Fazio, F. (2004) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1688-5 · Cited by 70
N-Substituted Adenosines as Novel Neuroprotective A1 Agonists with Diminished Hypotensive Effects
Knutsen, L. J. S., Lau, J. F., Petersen, H., Thomsen, C., Weis, J. U., Shalmi, M., Judge, M. E., Hansen, A. J., & Sheardown, M. J. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm960682u · Cited by 68
Cordeaux, Y., Briddon, S. J., Alexander, S. P. H., Kellam, B., & Hill, S. J. (2007) · The FASEB Journal · doi:10.1096/fj.07-8180com · Cited by 68
El‐Tayeb, A., Iqbal, J., Behrenswerth, A., Romio, M., Schneider, M., Zimmermann, H., Schrader, J., & Müller, C. E. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900538v · Cited by 67
Self-citationCaffeine Analogs: Structure-Activity Relationships at Adenosine Receptors
Daly, J. W., Hide, I., ller, C. E. M. U., & Shamim, M. T. (2008) · Pharmacology · doi:10.1159/000138813 · Cited by 65
Yang, H., Avila, M. Y., Peterson-Yantorno, K., Coca‐Prados, M., Stone, R. A., Jacobson, K. A., & Civan, M. M. (2005) · Current Eye Research · doi:10.1080/02713680590953147 · Cited by 65
Self-citationKalk, P., Eggert, B., Relle, K., Godes, M., Heiden, S., Sharkovska, Y., Fischer, Y., Ziegler, D., Bielenberg, G., & Hocher, B. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707319 · Cited by 63
Okamura, T., Kurogi, Y., Hashimoto, K., Sato, S., Nishikawa, H., Kiryu, K., & Nagao, Y. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.04.099 · Cited by 63
A3 Adenosine Receptor: Pharmacology and Role in Disease
Borea, P. A., Gessi, S., Bar‐Yehuda, S., & Fishman, P. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-89615-9_10 · Cited by 61
Elzein, E. O., Kalla, R. V., Li, X., Perry, T. D., Gimbel, A., Zeng, D., Lustig, D. A., Leung, K., & Zablocki, J. A. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7014815 · Cited by 60
Klotz, K., Vogt, H., & Tawfik-Schlieper, H. (1991) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00168610 · Cited by 59
A1 Receptors Ligands: Past, Present and Future Trends
Schenone, S., Brullo, C., Musumeci, F., et al. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610791268729 · Cited by 58
Medicinal Chemistry of the A3 Adenosine Receptor: Agonists, Antagonists, and Receptor Engineering
Jacobson, K. A., Klutz, A. M., Tosh, D. K., Ivanov, A. A., Preti, D., & Baraldi, P. G. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-89615-9_5 · Cited by 57
Self-citationJeong, L. S., Pal, S., Choe, S. A., Choi, W. J., Jacobson, K. A., Gao, Z., Klutz, A. M., Hou, X., Kim, H. O., Lee, H. W., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8008647 · Cited by 55
Self-citationRecent improvements in the development of A2B adenosine receptor agonists
Baraldi, P. G., Tabrizi, M. A., Fruttarolo, F., Romagnoli, R., & Preti, D. (2008) · Purinergic Signalling · doi:10.1007/s11302-008-9097-z · Cited by 55
Tracey, W. R., Magee, W. P., Oleynek, J. J., Hill, R. J. W., Smith, A. H., Flynn, D. M., & Knight, D. R. (2003) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00411.2003 · Cited by 53
Recent advances in adenosine receptor antagonist research
Hess, S. (2001) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.11.10.1533 · Cited by 52
Polosa, R., & Holgate, S. T. (2006) · Current Drug Targets · doi:10.2174/138945006777435236 · Cited by 52
[3H]ZM241385—an antagonist radioligand for adenosine A2A receptors in rat brain
Alexander, S. P. H., & Millns, P. J. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00899-2 · Cited by 52
Stewart, M., Steinig, A. G., Ma, C., Song, J., McKibben, B. P., Castelhano, A. L., & MacLennan, S. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.03.026 · Cited by 51
Recent Developments in Adenosine A2A Receptor Ligands
Cristalli, G., Müller, C. E., & Volpini, R. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-89615-9_3 · Cited by 51
Self-citationKecskés, M., Kumar, T. S., Yoo, L. S., Gao, Z., & Jacobson, K. A. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.04.027 · Cited by 49
Self-citationCaffeine versus theophylline for apnea of prematurity: A randomised controlled trial
Skouroliakou, M., Bacopoulou, F., & Markantonis, S. L. (2009) · Journal of Paediatrics and Child Health · doi:10.1111/j.1440-1754.2009.01570.x · Cited by 49
Adachi, H., Palaniappan, K. K., Ivanov, A. A., Bergman, N., Gao, Z., & Jacobson, K. A. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061278q · Cited by 47
Self-citationShah, U., & Hodgson, R. A. (2010) · PubMed · Cited by 47
Melman, A., Gao, Z., Kumar, D., Wan, T. C., Gizewski, E. T., Auchampach, J. A., & Jacobson, K. A. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.04.001 · Cited by 45
Self-citationPotent and Orally Bioavailable 8-Bicyclo[2.2.2]octylxanthines as Adenosine A1 Receptor Antagonists
Kiesman, W. F., Zhao, J. X., Conlon, P. R., Dowling, J. E., Petter, R. C., Lutterodt, F., Jin, X., Smits, G. J., Fure, M., Jayaraj, A. A., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0605381 · Cited by 43
Sherbiny, F. F., Schiedel, A. C., Maaß, A., & Müller, C. E. (2009) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-009-9299-7 · Cited by 42
Self-citationMelman, A., Wang, B., Joshi, B. V., Gao, Z., de Castro, S., Heller, C. L., Kim, S., Jeong, L. S., & Jacobson, K. A. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.08.007 · Cited by 42
Self-citationSaku, O., Saki, M., Kurokawa, M., Ikeda, K., Takizawa, T., & Uesaka, N. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.12.028 · Cited by 41
Luthra, P. M., Mishra, C. B., Jha, P. K., & Barodia, S. K. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.11.133 · Cited by 38
Rolofylline: a selective adenosine 1 receptor antagonist for the treatment of heart failure
Slawsky, M., & Givertz, M. M. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560802682213 · Cited by 38
Wang, Z., Wai, C., Avila, M. Y., Peterson-Yantorno, K., Stone, R. A., Gao, Z.-G., Joshi, B. V., Besada, P., Jeong, L. S., Jacobson, K. A., et al. (2009) · Experimental Eye Research · doi:10.1016/j.exer.2009.10.001 · Cited by 37
Self-citationStructure-Activity Relationships for 2-Substituted Adenosines at A 1 and A 2 Adenosine Receptors
Daly, J. W., Padgett, W. L., Secunda, S. I., Thompson, R. D., & Olsson, R. A. (2008) · Pharmacology · doi:10.1159/000139033 · Cited by 37
Volpini, R., Buccioni, M., Ben, D. D., Lambertucci, C., Lammi, C., Marucci, G., Ramadori, A. T., Klotz, K., & Cristalli, G. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900754g · Cited by 34
Adenosine A2A receptor dynamics studied with the novel fluorescent agonist Alexa488-APEC
Brand, F. J., Klutz, A. M., Jacobson, K. A., Fredholm, B. B., & Schulte, G. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.05.036 · Cited by 34
Self-citationKim, Y., Hechler, B., Gao, Z., Gachet, C., & Jacobson, K. A. (2009) · Bioconjugate Chemistry · doi:10.1021/bc9001689 · Cited by 34
Self-citationCharacterization of the A2B Adenosine Receptor from Mouse, Rabbit, and Dog
Auchampach, J. A., Kreckler, L. M., Wan, T. C., Maas, J. E., van der Hoeven, D., Gizewski, E. T., Narayanan, J., & Maas, G. E. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.148270 · Cited by 34
Recent improvements in the development of A2B adenosine receptor agonists
Baraldi, P. G., Tabrizi, M. A., Fruttarolo, F., Romagnoli, R., & Preti, D. (2009) · Purinergic Signalling · doi:10.1007/s11302-009-9140-8 · Cited by 33
Advances in pharmacologic agents in imaging: New A2A receptor agonists
Cerqueira, M. D. (2006) · Current Cardiology Reports · doi:10.1007/s11886-006-0022-1 · Cited by 32
Zablocki, J. A., Wu, L., Shryock, J. C., & Belardinelli, L. (2004) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026043450998 · Cited by 31
Pal, S., Choi, W. J., Choe, S. A., Heller, C. L., Gao, Z., Chinn, M., Jacobson, K. A., Hou, X., Lee, S. K., Kim, H. O., et al. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.03.034 · Cited by 28
Self-citationKiesewetter, D. O., Lang, L., Ma, Y., Bhattacharjee, A. K., Gao, Z., Joshi, B. V., Melman, A., de Castro, S., & Jacobson, K. A. (2009) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2008.10.003 · Cited by 27
Self-citationAdenosine Receptor Ligands and PET Imaging of the CNS
Bauer, A., & Ishiwata, K. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-89615-9_19 · Cited by 25
Auchampach, J. A., Gizewski, E. T., Wan, T. C., de Castro, S., Brown, G. G., & Jacobson, K. A. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.11.009 · Cited by 23
Self-citationGao, Z., & Jacobson, K. A. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01552-2 · Cited by 22
Self-citationEastwood, P. R., González, J., Paredes, S., Fonquerna, S., Cardús, A., Alonso, J. A., Nueda, A., Domènech, T., Reinoso, R. F., & Vidal, B. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.01.077 · Cited by 21
Adenosine A1 antagonists and the cardiorenal syndrome
Gottlieb, S. S. (2008) · Current Heart Failure Reports · doi:10.1007/s11897-008-0017-x · Cited by 20
Enhanced A3 adenosine receptor selectivity of multivalent nucleoside-dendrimer conjugates
Klutz, A. M., Gao, Z., Lloyd, J., Shainberg, A., & Jacobson, K. A. (2008) · Journal of Nanobiotechnology · doi:10.1186/1477-3155-6-12 · Cited by 20
Self-citationEastwood, P. R., González, J., Paredes, S., Nueda, A., Domènech, T., Alberti, J. J., & Vidal, B. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.01.045 · Cited by 19
Saku, O., Saki, M., Kurokawa, M., Ikeda, K., Uchida, S., Takizawa, T., & Uesaka, N. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.04.058 · Cited by 18
Ishikawa, J., Mitani, H., Bandoh, T., Kimura, M., Totsuka, T., & Hayashi, S. (1998) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(97)00116-2 · Cited by 15
Bedford, S. T., Benwell, K. R., Brooks, T., Chen, I., Comer, M., Dugdale, S., Haymes, T., Jordan, A. M., Kennett, G. A., Knight, A. R., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.08.040 · Cited by 11
Beattie, D., Brearley, A., Brown, Z., Charlton, S. J., Cox, B. J., Fairhurst, R. A., Fozard, J. R., Gedeck, P., Kirkham, P., Meja, K. K., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.11.131 · Cited by 10
Zannikos, P., Jensen, B. K., Boutouyrie, B. X., Tripp, L., Yongyi, L., McGowan, T., Waldman, S. A., & Greenberg, H. E. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/00912700022009503 · Cited by 5
Shen, A. Y., Li, H.-F., & Lu, S. I. (1999) · Drug Development Research · doi:10.1002/(sici)1098-2299(199905)47:1<45::aid-ddr6>3.0.co;2-u
Cited by
Fredholm, B. B., IJzerman, A. P., Jacobson, K. A., Linden, J., & Müller, C. E. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003285 · Cited by 1,301
Self-citationThe ectonucleotidases CD 39 and CD 73: Novel checkpoint inhibitor targets
Allard, B., Longhi, M. S., Robson, S. C., & Stagg, J. (2017) · Immunological Reviews · doi:10.1111/imr.12528 · Cited by 927
Adenosine receptors as drug targets — what are the challenges?
Chen, J.-F., Eltzschig, H. K., & Fredholm, B. B. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3955 · Cited by 895
The adenosine pathway in immuno-oncology
Allard, B., Allard, D., Buisseret, L., & Stagg, J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0382-2 · Cited by 586
Shelton, J., Lu, X., Hollenbaugh, J. A., Cho, J. H., Amblard, F., & Schinazi, R. F. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00209 · Cited by 409
Metadata
- Authors
- Müller, C. E., & Jacobson, K. A.
- Venue
- Biochimica et Biophysica Acta (BBA) - Biomembranes
- Publisher
- Elsevier BV
- Published
- 2011-05
- Volume
- 1808
- Issue
- 5
- Pages
- 1290-1308
- ISSN
- 0005-2736 (ISSN-L)
- OpenAlex
- W2093777829
- Cited by
- 431
- References
- 130
- FWCI
- 16.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.